Market alerts

Launching the Genesis Mission

Initial operating capability demonstration for at least one challenge

Realigning United States Core Childhood Vaccine Recommendations With Best Practices From Peer, Developed Countries

CDC and ACIP to review scientific assessment and clinical data and take appropriate steps to update schedule

Presidential Determination on Major Drug Transit or Major Illicit Drug Producing Countries for Fiscal Year 2026

Expected additional aggressive Mexican efforts against cartels

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States

Tariffs effective for other companies

Sequestration Order for Fiscal Year 2027 Pursuant to Section 251A of the Balanced Budget and Emergency Deficit Control Act, as Amended

Sequestration reductions take effect for FY2027

Delivering Gold Standard Childhood Vaccine Recommendations for Americans

HHS Task Force on Safer Childhood Vaccines presents plans to President through Assistant to the President for Domestic Policy

Launching the Genesis Mission

First annual report to President on Platform status, outcomes, and partnerships

Continuation of the National Emergencies With Respect to the Southern Border of the United States and Cartels and Other Transnational Organizations

Proclamation 10886 and EO 14157 one-year continuation expires unless renewed

Continuation of the National Emergencies With Respect to the Southern Border of the United States and Cartels and Other Transnational Organizations

EO 14193, EO 14194, and EO 14195 one-year continuation expires unless renewed

Continuation of the National Emergency With Respect to Trade Practices That Contribute to Large and Persistent Annual United States Goods Trade Deficits

Continued national emergency expires unless further extended

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States

Zero tariff rate expires for companies with MFN pricing agreements

Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States

20% onshoring rate increases to 100%

Regulatory Relief for Certain Stationary Sources To Promote American Chemical Manufacturing Security

This proclamation grants a 2-year exemption from certain EPA emissions-control requirements (the HON Rule) for specific

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs federal agencies to accelerate research, regulatory review, and patient access to psychedel

Regulatory Relief for Certain Stationary Sources To Promote American Chemical Manufacturing Security

This proclamation grants a 2-year exemption from certain EPA emissions-control requirements (the HON Rule) for specific

Additional Rescissions of Harmful Executive Orders and Actions

This executive order revokes 18 additional Biden-era executive actions, building on an earlier January 2025 order that r

Defending American Companies and Innovators From Overseas Extortion and Unfair Fines and Penalties

This memorandum directs multiple agencies to investigate and counter foreign tax and regulatory practices—particularly d

Increasing Medical Marijuana and Cannabidiol Research

This executive order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of

Unlocking Cures for Pediatric Cancer With Artificial Intelligence

This executive order directs the Make America Healthy Again (MAHA) Commission and health agencies to leverage artificial